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Whole breast irradiation represents an integral part of combined breast-conserving treat-
ment of early breast cancer. A new concept includes replacing traditionally fractionated
whole breast postoperative radiotherapy by accelerated partial breast irradiation. The lat-
ter involves a variety of techniques and may be applied intraoperatively or shortly after the
surgery. The intraoperative techniques include photon or electron external beam irradiation
and interstitial high dose rate (HDR) brachytherapy, whereas the postoperative techniques
comprise interstitial brachytherapy, be it HDR, pulse dose rate (PDR) or low dose rate (LDR),reast cancer
djuvant radiotherapy
hole breast irradiation
ccelerated partial breast
rradiation
intracavitary brachytherapy and external beam radiotherapy using electrons, photons or
protons. This article presents accelerated partial breast irradiation techniques, ongoing
phase III trials evaluating their value and recommendations for clinical practice.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
z.o.o. All rights reserved.
as those seen after WBI. Such a poor outcome might. Background
hole breast irradiation (WBI) represents an integral part of
ombined breast-conserving treatment of early breast cancer.
he outcome of this procedure is similar to that of radical
astectomy.1–6 Postoperative radiotherapy reduces the risk
f local recurrence, thus enhancing the chance for breast
onservation, and increases the rate of 10-year survival by
%.6 Conventionally fractionated radiotherapy usually lasts
–7 weeks, which is associated with prolonged hospitalisation
r the necessity of reporting at hospital for regular proce-
ures. Radiotherapy following breast conserving surgery is
ften delayed, which may deteriorate treatment outcome.7–10
ccelerated partial breast irradiation (APBI) may be an alter-
ative for a standard postoperative radiotherapy. The method
nvolves a delivery of a radiation dose within a shortened
eriod of time and to a limited area of the breast including the
umour bed with a margin. The fraction size is higher than
∗ Corresponding author. Tel.: +48 58 349 22 70; fax: +48 58 349 22 10.
E-mail address: aczufryn@wp.pl (A. Kacprowska).
507-1367/$ – see front matter © 2011 Greater Poland Cancer Centre, Poland
oi:10.1016/j.rpor.2011.08.003with standard treatment and the entire therapy comprises
usually 1–10 fractions administered over 1–5 days. Potential
beneﬁts of APBI include reduction of treatment costs, saving
of time, shorter radiotherapy waiting lists, convenience for
patients, less adverse effects and better quality of life.
The concept of APBI is based on the observation that most
local recurrences tend to occur in a close proximity of the
tumour bed and the probability of developing new cancer foci
far from the tumour bed is the same for WBI and non-WBI
patients. Furthermore, in patients treated with WBI, the like-
lihood of developing cancer at a remote site of the irradiated
breast is similar to that in the contralateral breast.2,6,11–13
Early attempts at the application of ABPI using external
beam radiotherapywere discouraging. The rates of local recur-
rence following the use of this technique were twice as high
14,15have been caused by inadequate patient selection, subopti-
mal surgery and imprecise radiotherapy treatment planning.
Results of further studies on APBI free of these shortcom-
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Fig. 1 – Insertion of the ELIOT applicator into the excision
cavity during breast conserving surgery.
Fig. 2 – Electron beam intra-operative radiotherapy.
Courtesy: Prof. Roberto Orecchia.
Fig. 3 – Mobile intraoperative radiation device (Intrabeam,
ZEISS Corporation, Germany).Courtesy: Prof. Roberto Orecchia.
ings were more promising.16,17 Note was taken, for example,
that surgery should obligatorily be preceded by mammogra-
phy. Additionally, histological type and size of tumour were
taken into account in patient selection, as was an appropriate
tumour-free margin. More emphasis was also put on precise
radiotherapy treatment planning.
2. APBI techniques
2.1. External beam intraoperative radiotherapy (IORT)
Intraoperative radiotherapy involves a delivery of a single high
dose of photons or electrons to a target volume identiﬁed dur-
ing a surgical procedure. To this end, dedicated applicators are
inserted into the excision cavity.
Electron beam intra-operative radiotherapy (ELIOT) uses
electron beam with energy of 3–12MeV to deliver a dose of
21Gy prescribed to the 90% isodose at the depth of 1.5–3 cm
(Figs. 1 and 2). Prior to radiotherapy, a shield is placed on
the chest wall to protect underlying tissues. The European
Institute of Oncology in Milan has the longest experience
in this technique, as it has used it since 1999.18 Recently,
results have been reported for 1822 patients treated with APBI
between 2000 and 2008. The most common adverse effects
were fat necrosis and ﬁbrosis, which occurred in 4.2% and
1.8% of patients, respectively. After the median follow-up of
36.1 months, the rates of local recurrence, new primary can-
cer foci in the irradiated breast and distant metastases wereCourtesy: Prof. Michael Baum.
2.3%, 1.3% and 1.4%, respectively. The rates of 5- and 10-year
overall survival were 97.4% and 89.7%, respectively.19
The other currently used IORT technique is Targeted Intra-
Operative Radiotherapy (TARGIT) (Figs. 3 and 4). This modality
includes insertion of a spherical applicator into a lumpectomy
bed and delivery of 50kV photon radiation. The size of the
applicator depends on the bed volume. With the most com-
monly used technique, a dose of 20Gy is achieved at 2mm
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Fig. 4 – Targeted Intra-Operative Radiotherapy (TARGIT).
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Fig. 5 – Flexible plastic catheters inserted into the tumourourtesy: Prof. Michael Baum.
rom the surface of the applicator, falling rapidly to 5Gy at
cm from the surface. Irradiation is given over 20–25min.20
External beam IORT offers the beneﬁt of delivering radio-
herapy exactly to the target volume with little risk of
eographical miss, effective protection of healthy tissues,
onvenience of use and shortening of total treatment time
y virtue of the application of just one radiotherapy frac-
ion. Limitations of this modality include the absence of ﬁnal
istopathological report at the time of radiotherapy, patient’s
onger stay at the operation theatre under general anaesthe-
ia and the potential risk of late complications related to the
dministration of single high-dose radiation.
.2. Interstitial brachytherapy
nterstitial brachytherapy resembles the method routinely
sed to boost a dose for the tumour bed after WBI. Several
atheters, the number ofwhich depends on the size and shape
f the site left after an excised tumour, are inserted into the
umour bed under general anaesthesia (Fig. 5). Then, a target
olume is set to include the bed and a margin of 1–2 cm. An
ptimal dose distribution is obtained by establishing the dwell
ositions for radioactive seed in particular catheters placed
n the breast. Treatment is carried out using the afterloading
Fig. 6 – MammoSite brachytherbed.
technique (HDRs—high dose rates, PDRs—pulse dose rates,
LDRs—low dose rates). The most commonly used fractiona-
tion schedule in APBI employing 192Ir HDR unit involves the
administration of 34Gy in 10 fractions over 5 days (2 fractions
a day given at intervals of at least 6h). The technique allows
a good control of doses delivered to the skin and enables the
shape of a reference isodose to be adjusted to the shape of
the tumour bed.21 This modality, however, requires high skills
and experience from the radiation oncologist. If postponed
until after the surgery, itmay necessitate another procedure in
general anaesthesia. Another limitation is related to inhomo-
geneous dose distribution in the implant due to the presence
of “hot spots”. The results of phase I and II trials using APBI
interstitial brachytherapy are presented in Table 1.
2.3. Intracavitary brachytherapy
MammoSite is the most commonly used device for intracav-
itary brachytherapy. It is a silicone balloon with a centrally
placed catheter holding a source of HDR radiation (Fig. 6). The
balloon is inserted into the tumour bed intraoperatively or
under USG guidance a few days after the surgery (Fig. 7). Hav-
ing been placed in the bed, the balloon is inﬂated with a saline
solution and a contrast agent to ﬁll up the whole tumour cav-
ity. The minimum acceptable distance between the balloon
and the skin is 5mm, and the recommended distance is 7mm.
apy device. (Hologic, Inc.)
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Table 1 – Recent studies of APBI with interstitial brachytherapy.
Author (Ref.) No. of
patients
Median
follow-up
(months)
RT technique and dose In-breast
recurrence
Cosmesis
good/excellent
Grade 3/4 toxicity
Arthur22 99 84 LDR: 45Gy/3.5–5 days
HDR: 34Gy/10bid/5 days
4% at 5 years NR 18% for LDR; 4% for HDR
Polgar23 45 133 HDR: 30.3–36.4Gy/7fr/4 days 9.3% at 12 years 78% 1 G3 ﬁbrosis1 fat necrosis
King24 51 75 LDR: 45Gy/4 days
HDR: 32Gy/8bid/4 days
1.9% 75% 8%
Vicini25 199 65 LDR: 50Gy/4 days
HDR: 32–34Gy/8–10bid
1% at 5 years 99% 0
Abbreviations: bid, twice a day; HDR, high dose radiotherapy; LDR, low dose radiotherapy; NR, not reported; RT, radiotherapy.
Fig. 7 – Illustration of MammoSite balloon inside tumour
on a spherical applicator surface or WBI of 40–56Gy withresection cavity.
Reducing the skin spacing substantially increases the risk of
worse cosmetic effects.26 The volume to be irradiated covers
the tumour bed with a margin of 1–1.5 cm and the duration of
the therapy is approximately 1 week. The dose is fractionated
aswith interstitial HDR brachytherapy, i.e. 34Gy in 10 fractions
over 5 days. The method is simple, reproducible, fast to learn
and easy to plan. It is less invasive than interstitial brachyther-
apy. However, the dose cannot be redistributed to ﬁt possible
irregularities of the tumour bed or reduced for the adjacent
skin and chest wall. Additionally, the cost of the device is rel-
atively high. Women with small breasts may ﬁnd this method
more painful and toxic than those with bigger breasts.
So far, results of using MammoSite have been promising,
with low rates of local recurrence (0–5.7%); however, the short
follow-up periods of 7–65 months call for some caution. The
cosmetic outcome is similar to that with WBI or PBI using
interstitial brachytherapy.27 Most common adverse effects
include erythema, dry and moist desquamation, telangiec-
tasias, fat necrosis and development of seroma.
2.4. Postoperative external beam radiotherapyAPBI may be performed by postoperative irradiation of the
tumour bed with external beam. Treatment may include
multi-ﬁeld 3D conformal techniques, intensity modulatedradiation therapy (IMRT) or proton beam. The beneﬁts of this
modality include availability of ﬁnal histopathological report
at therapy onset, use of standard radiotherapy techniques,
possibility to use widely available therapy planning and deliv-
ery equipment, and low invasiveness. As compared to the
other APBI techniques, external beam radiotherapy offers a
very homogeneous dose distribution. On the other hand, an
irradiated volume has to be larger, as it encompasses the
tumour bed alongwith amargin to allow for respiratorymobil-
ity and possible differences in patient setup at particular
radiotherapy fractions.28
Current experience with this method is based on small-
sized studies performed in single institutions. Although the
results seem to be promising, typical follow-up periods of
10–18 months are too short for a reliable evaluation of this
procedure.29–31
3. Phase III trials comparing WBI and APBI
So far, results of only two prospective randomised stud-
ies comparing WBI and APBI have been published.32,33 The
study carried out by the National Institute of Oncology
in Hungary included 258 patients who underwent breast-
conserving surgery and had negative margins of T1 N0-1mi
breast cancer.32 The patients assigned to PBI arm received
interstitial HDR brachytherapy at a dose of 36.4Gy in 7 frac-
tions or limited-ﬁeld electron beam irradiation at a dose of
50Gy in 25 fractions. Standard arm included conventionally
fractionatedWBI (50Gy in 25 fractions). The 5-year local recur-
rence rates with PBI andWBI were 4.7% and 3.4%, respectively
(insigniﬁcant difference). There were also no differences for
overall survival and disease-free survival. A very good cos-
metic result was achieved in 77.6% and 62.9% patients treated
with PBI and WBI, respectively (p=0.009).
Recently, results of TARGIT-A, a multicentre, international
trial, were presented.33 This study included 2232 patients
aged 45 and older with early breast cancer. After having
undergone breast-conserving surgery, the patients were ran-
domly assigned to receive either intraoperative PBI of 20Gyor without a boost to the tumour bed of 10–16Gy (depend-
ing on the centre’s decision). The PBI group patients with
lobular carcinoma, extensive intraductal component or other
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Table 2 – Randomised trials comparing APBI and WBI.
Trial (Ref.) Main inclusion criteria Experimental arm Control arm
TARGIT33,34 Stage I, II
T≤3
Age≥45 years
cN0
Negative margins
IORT—single dose of 20Gy, if
high riska WBI is added
(45–50Gy)
WBI 45–50Gy in 15–25 fr,
optional boost
10–16Gy in 5–8 fr
ELIOT35,36 Post quadrantectomy
Stage I, II
T≤2.5 cm
Age>48 years
N0, N1
Negative margins
IORT—single dose of 21Gy with
electrons
WBI 50Gy in 25 fr with
boost 10Gy in 5 fr
GEC-ESTRO37 Post lumpectomy
Stage 0, I, II
T≤3 cm
Age≥40 years
≤1 micrometastasis in axilla
Margins≥2mm (≥5mm for DCIS)
Interstitial brachytherapy: HDR
32Gy/8 fr, bid or
HDR 30.3Gy/7 fr, bid or PDR
50Gy in hourly fractions of
0.6–0.8Gy
WBI 50–54Gy, optional
boost 10Gy
NSABP
B-39/RTOG38
Post lumpectomy
Stage 0, I, II
T≤3 cm
pN0, N1
Negative margins
Age≥18 years
Interstitial brachytherapy
34Gy/10 fr or MammoSite
balloon catheter 34Gy/10 fr or
3D-CRT 38.5Gy/10 fr
WBI 50–50.4Gy, optional
boost to 60–66.6Gy
RAPID/Ontario Clinical
Oncology Group39
Post lumpectomy
Stage 0, I, II
T≤3 cm
Age≥40 years
pN0
Negative margins
3D CRT 38.5Gy/10 fr/5–8 days WBI 42.5Gy/16 fr/22 days or
50Gy/25 fr/35 days (large
breast), optional boost
10Gy/4–5 fr
IMPORT-LOW40 Post lumpectomy
Stage I
T≤2 cm
Age≥50 years
pN0
Margins≥2mm
EBRT based on IMRT: Arm 1:
40Gy/15 fr to region of primary
tumour and 36Gy/15 fr to low
risk areas
Arm 2: PBI 40Gy/15 fr
WBI 40Gy/15 fr/3 weeks
IRMA41 Age≥49 years
Post conservative breast surgery
T<3 cm
pN0-N1
Margins≥2mm
3D CRT 38.5Gy/10 fr/5 days WBI 45Gy/18 fr, or 50Gy/25
fr, or 50.4Gy/28 fr, optional
boost 10–16Gy/5–8 fr
Abbreviations: 3DCRT, three-dimensional conformal radiotherapy; bid, twice a day; DCIS, ductal carcinoma in situ; EBRT, external beam radiother-
apy; ELIOT, electron intraoperative radiotherapy technique; GEC-ESTRO, Groupe Europeen de Curietherapie-European Society for Therapeutic
Radiology and Oncology; HDR, high dose radiotherapy; IMRT, intensity modulated radiotherapy; IMPORT-LOW, intensity modulated and partial
organ radiotherapy trial; IORT, intraoperative radiotherapy; PBI, partial breast irradiation; PDR, pulsed dose rate; TARGIT, targeted intraoperative
radiotherapy; WBI, whole breast irradiation.
a Pre-speciﬁed criteria, e.g., unsuspected lobular carcinoma, lymphovascular invasion, and others.
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VI), were subsequently administered additional WBI. After a
edian follow-up of 4 years, the rates of local recurrence in
he group treated with PBI and WBI were respectively 1.2%
nd 0.95% (p=0.41). Radiotherapy toxicity (RTOG grade 3 and
) in the PBI and WBI groups occurred in 0.5% and 2.1% of
atients, respectively (p=0.002), while seroma requiring more
han three aspirations occurred in 2.1% and 0.8% of patients,
espectively (p=0.012). There was no difference between the
roups in the incidence of haematoma, delayed wound heal-
ng or infections.4. Ongoing studies
At present, several randomised studies are being conducted to
compare treatment results using WBI and APBI in early-stage
breast cancer patients after breast conserving surgery.33–41
Main inclusion criteria and treatment methods are shown in
Table 2. Particular studies differ considerably in terms of radio-
therapy techniques, dose fractionation and planning target
volume.42 The trials also vary in patient selection with regard
to age, histological type of cancer and presence of metastases
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to axillary lymph nodes. These differences may hinder inter-
study comparison and metaanalyses.
5. Conclusion
There are reasonable biological rationales for using APBI and
the available results of this approach in selected groups of
patients are encouraging. However, as local recurrences in
breast cancer and some radiotherapy-speciﬁc complications
may emerge aftermany years following treatment, full assess-
ment of APBI value will only be possible after a long follow-up.
Essential in this respect will be the results of ongoing large
randomised clinical studies. The current knowledge does not
allow to identify an optimal APBI technique. In consequence,
this method may not yet be recommended as a routine alter-
native for WBI. Some scientiﬁc societies have already allowed
restricted use of APBI in clinical practice in carefully selected
patient groups (Table 3). The National Comprehensive Cancer
Network (NCCN) recommends encouraging patients to partic-
ipate in clinical trials. If not trial eligible, NCCN allows the
use of APBI in accordance with ASTRO recommendations.43
Most recently, around a half of the panelists of the Expert Con-
sensus on the Primary Therapy of Early Breast Cancer in St.
Gallen 2011, accepted the use of APBI as deﬁnitive treatment in
selected patients, and a strongmajority accepted this method
in patients above the age of 70.48
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